Day 1, Thursday, May 14th
08:00–09:15 Pre-COMy Symposium
09:15–09:25 COMy 2026 kick-off:
Welcome by the Congress Chairs
09:25–10:40 Session 1: Advances in biology
Moderators: Hervé Avet-Loiseau, France; Rafael Fonseca, USA
09:25–09:40 Genomics: Francesco Maura, USA
09:40–09:55 Microenvironment: Madhav Dhodapkar, USA
09:55–10:10 Role of immune microenvironment in myeloma: Paola Neri, Canada
10:10–10:25 Liquid biopsies: Joaquín Martínez López, Spain
10:25–10:40 Discussion: All session faculty and Gareth Morgan, USA + Mehmet Samur, USA
10:40–11:00 Coffee Break
11:00–12:15 Session 2: New response criteria
Moderators: Rafat Abonour, USA; Heinz Ludwig, Austria
11:00–11:15 Historical perspective: Joan Bladé, Spain
11:15–11:30 Summary of new response criteria: Shaji Kumar, USA
11:30–11:45 Role of MRD: Bruno Paiva, Spain
11:45–12:00 Role of SFL chains and role of urine: Kwee Yong, UK
12:00–12:15 Mass spectrometry: Noemi Puig, Spain
12:15–13:30 Industry-supported Lunch Symposium
13:30–14:00 Lunch Break
14:00–15:15 Industry-supported Lunch Symposium
15:15–16:30 Session 3: Mechanisms of resistance
Moderators: Faith Davies, USA; Marc Raab, Germany
15:15–15:30 Resistance to CAR T: Carlos Fernández de Larrea, Spain
15:30–15:45 Résistance to bispecifics: Hermann Einsele, Germany
15:45–16:00 Resistance to ImiDs: Keith Stewart, Canada
16:00–16:15 Overcoming resistance: Nizar Bahlis, Canada
16:15–16:30 Discussion: All session faculty and Malin Hultcrantz, USA + Michael O’Dwyer, Ireland
16:30–16:50 Coffee Break
16:50–18:05 Session 4: Plenary lectures I
Moderators: Wee Joo Chng, Singapore; Noopur Raje, USA
16:50–17:05 Smoldering multiple myeloma: María-Victoria Mateos, Spain
17:05–17:20 Waldenstrom Disease: Steven Treon, USA
17:20–17:35 Amyloidosis: Suzanne Lentzsch, USA
17:35–17:50 Discussion: All session faculty and Rahul Banerjee, USA + Robert Orlowski, USA
17:50-19:00 Session 5: How to manage high risk disease
Moderators: Meral Beksaç, Turkey; Vania Hungria, Brazil
17:50-18:05 New classification: Jill Corre, France
18:05-18:20 Extra-medullary disease: Saad Usmani, USA
18:20-18:35 Plasma cell leukemia: Cyrille Touzeau, France
18:35-18:50 Functional high-risk: Martin Kaiser, UK
18:50-19:00 Discussion: All session faculty and Luciano Costa, USA + and Rakesh Popat, UK
Day 2, Friday, May 15th
07:00–08:00 Session 6: TBA
08:00–09:15 Industry-supported Early Morning Symposium 
09:15–10:30 Industry-supported Morning Symposium 
10:30–10:50 Coffee Break
10:50–12:05 Session 7: Cure: hope, hype or reality?
Moderators: Kenneth Anderson, USA; Jean-Luc Harousseau, France
10:50–11:05 My definition of cure: Sagar Lonial, USA
11:05–11:20 My definition of cure: Vincent Rajkumar, USA
11:20–11:35 My definition of cure: Jesús San Miguel, Spain
11:35–11:50 Precursor disease and cure: Irene Ghobrial, USA
11:50–12:05 Discussion: All session faculty and Catarina Geraldes, Portugal
12:05–13:20 Industry-supported Lunch Symposium
13:20–13:50 Lunch Break
13:50–14:25 Session 8: COMy Awards and lecture series
14:25–15:40 Industry-supported Afternoon Symposium
15:40–16:40 Session 9: IMS Session
16:40-17:55 Industry-supported Afternoon Symposium 
17:55-18:15 Coffee Break
18:15–19:00 Session 10: State-of-the-art management
Moderators: Thierry Facon, France; Francesca Gay, Italy
18:15–18:30 Elderly patients: Salomon Manier, France
18:30–18:45 TE patients: Aurore Perrot, France
18:45–19:00 Bone disease: Evangelos Terpos, Greece
19:00–19:30 Session 11: Conclusions of the day
Day 3, Saturday, May 16th
07:00–08:00 Session 12: TBA
08:00–09:15 Industry-supported Early Morning Symposium 
09:15–10:30 Industry-supported Morning Symposium
10:30–10:50 Coffee Break
10:50–12:05 Session 13: COMy debates
Moderators: Michel Delforge, Belgium; Thomas Martin, USA
10:50–11:00 1st relapse, the case for CAR T cells: Luciano Costa, USA
11:00–11:10 1st relapse, the case for Ab drug conjugates: Meletios Dimopoulos, Greece
11:10–11:25 Discussion: Debate faculty and Roman Hajek, Czech Republic + Xavier Leleu, France
11:25–11:35 Doublet maintenance: Paul Richardson, USA
11:35–11:45 Single agent maintenance: Pieter Sonneveld, Netherlands
11:45–12:05 Discussion: Debate faculty and Hartmut Goldschmidt, Germany + Andrew Spencer, Australia
12:05–13:20 Industry-supported Lunch Symposium
13:20–13:50 Lunch Break
13:50–14:50 Session 14: The hard-to-treat patients
Moderators: Joshua Richter, USA; TBA
13:50-14:05 The case for peptide conjugates: TBA
14:05-14:20 NDMM under dialysis: TBA
14:20-14:35 TBA
14:35-14:50 Discussion: All session faculty and Doris Hansen, USA + Hira Mian, Canada
14:50–16:05 Industry-supported Afternoon Symposium
16:05–17:20 Industry-supported Afternoon Symposium
17:20–17:40 Coffee Break
17:40–18:55 Session 15: Plenary Lectures II
Moderators: Joy Ho, Australia; TBA
17:40-17:55 35 years of myeloma trials: Philippe Moreau, France
17:55-18:10 Genomics guiding therapy: Nikhil Munshi, USA
18:10-18:25 CAR T cells: past, present and future: TBA
18:25-18:40 The future of multiple myeloma therapy: Kenneth Anderson, USA
18:40-18:55 Discussion: All session faculty and Mohamad Mohty, France + Arnon Nagler, Israel
18:55–19:30 Session 16: Conclusions of the day
Day 4, Sunday, May 17th – ONLINE ONLY
Multiple Myeloma Communications I
Break
Multiple Myeloma Communications II
Conclusion and see you next year!